Lipoprotein(a) (Lp(a)) is an established risk factor for multiple cardiovascular diseases. Several lines of evidence including mechanistic, epidemiologic, and genetic studies support the role of Lp(a) as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis/calcific aortic valve disease (AS/CAVD). Limited therapies currently exist for the management of risk associated with elevated Lp(a), but several targeted therapies are currently in various stages of clinical development. In this review, we detail evidence supporting Lp(a) as a causal risk factor for ASCVD and AS/CAVD, and discuss approaches to managing Lp(a)-associated risk
A number of epidemiologic studies have demonstrated a strong association between increasing lipoprot...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
Lipoprotein(a) (Lp(a)) is an established risk factor for multiple cardiovascular diseases. Several l...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
Atherosclerosis is a chronic and progressive inflammatory process beginning early in life with late ...
Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor, and growing evidence indicates ...
Aims The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovas...
Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a...
Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a...
Lipoprotein(a) is an underrecognized, but significant genetic risk factor for atherosclerotic cardio...
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and cau...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a)...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
A number of epidemiologic studies have demonstrated a strong association between increasing lipoprot...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
Lipoprotein(a) (Lp(a)) is an established risk factor for multiple cardiovascular diseases. Several l...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
Atherosclerosis is a chronic and progressive inflammatory process beginning early in life with late ...
Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor, and growing evidence indicates ...
Aims The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovas...
Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a...
Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a...
Lipoprotein(a) is an underrecognized, but significant genetic risk factor for atherosclerotic cardio...
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and cau...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a)...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
A number of epidemiologic studies have demonstrated a strong association between increasing lipoprot...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates eviden...